HK1205112A1 - Enzyme-activating compounds and compositions - Google Patents
Enzyme-activating compounds and compositionsInfo
- Publication number
- HK1205112A1 HK1205112A1 HK15105567.5A HK15105567A HK1205112A1 HK 1205112 A1 HK1205112 A1 HK 1205112A1 HK 15105567 A HK15105567 A HK 15105567A HK 1205112 A1 HK1205112 A1 HK 1205112A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- enzyme
- compositions
- activating compounds
- activating
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679129P | 2012-08-03 | 2012-08-03 | |
| PCT/US2013/053648 WO2014022858A1 (fr) | 2012-08-03 | 2013-08-05 | Composés et compositions activant des enzymes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205112A1 true HK1205112A1 (en) | 2015-12-11 |
Family
ID=50028583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15105567.5A HK1205112A1 (en) | 2012-08-03 | 2015-06-11 | Enzyme-activating compounds and compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9249116B2 (fr) |
| EP (1) | EP2880020B1 (fr) |
| JP (1) | JP6265558B2 (fr) |
| KR (1) | KR102157912B1 (fr) |
| CN (1) | CN104981461B (fr) |
| AU (1) | AU2013296187B2 (fr) |
| BR (1) | BR112015002357B1 (fr) |
| CA (1) | CA2879798C (fr) |
| HK (1) | HK1205112A1 (fr) |
| MX (1) | MX364002B (fr) |
| RU (1) | RU2652989C2 (fr) |
| WO (1) | WO2014022858A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008134474A2 (fr) * | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions et procédés comportant des inducteurs de mort cellulaire et d'activation de procaspase |
| US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
| KR20170092634A (ko) | 2014-12-05 | 2017-08-11 | 에이엔2에이치 디스커버리 리미티드 | 파킨 리가제 활성화 방법 및 조성물 |
| ES2906763T3 (es) | 2015-06-05 | 2022-04-20 | Univ Illinois | Terapia combinada de PAC-1 |
| KR102637041B1 (ko) | 2015-11-12 | 2024-02-16 | 현대모비스 주식회사 | 차량 위치 정보 확인 시스템 |
| US10308617B2 (en) | 2016-06-03 | 2019-06-04 | An2H Discovery Limited | Triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| MX2020004991A (es) | 2017-11-17 | 2022-02-10 | Univ Illinois | Terapia oncológica mediante la degradación de la señalización dual de mek. |
| US10889553B2 (en) | 2017-12-01 | 2021-01-12 | Nysnobio Ireland Dac | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same |
| AU2019354771A1 (en) | 2018-10-05 | 2021-04-01 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| EP3974434A4 (fr) | 2019-05-21 | 2023-11-08 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Dérivés de macrolides, leur procédé de préparation et leur application |
| CN110759937B (zh) * | 2019-11-12 | 2021-12-28 | 吉林大学 | 一种含硼有机电致发光化合物及其制备方法和应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| CN101184491A (zh) * | 2005-05-26 | 2008-05-21 | 伊利诺伊大学评议会 | 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导 |
| WO2008134474A2 (fr) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions et procédés comportant des inducteurs de mort cellulaire et d'activation de procaspase |
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| WO2007008529A2 (fr) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc | Agents modificateurs de l'absorption du cholesterol cellulaire |
| CN101712655B (zh) * | 2008-10-08 | 2012-05-23 | 秦引林 | 一种乙酰胺类衍生物及其在制药中的应用 |
| JP5896746B2 (ja) * | 2009-02-09 | 2016-03-30 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 個別化された抗癌薬としてのプロカスパーゼ活性化化合物の設計、合成および評価 |
| CN101565409B (zh) * | 2009-03-20 | 2011-09-07 | 深圳市湘雅生物医药研究院 | 哌嗪或高哌嗪草酰肼类化合物及其制备方法和用途 |
| CN101941953B (zh) * | 2010-02-10 | 2013-04-10 | 深圳市湘雅生物医药研究院 | 含氮杂环取代的酰肼类化合物及其制备方法和用途 |
| KR101912962B1 (ko) * | 2010-12-13 | 2018-10-29 | 바스프 에스이 | 표백 촉매 |
| CN102838567B (zh) * | 2011-06-23 | 2014-12-31 | 深圳市湘雅生物医药研究院 | 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途 |
| US8916705B2 (en) | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
-
2013
- 2013-08-05 JP JP2015525644A patent/JP6265558B2/ja active Active
- 2013-08-05 KR KR1020157005002A patent/KR102157912B1/ko active IP Right Grant
- 2013-08-05 AU AU2013296187A patent/AU2013296187B2/en active Active
- 2013-08-05 EP EP13825092.3A patent/EP2880020B1/fr active Active
- 2013-08-05 MX MX2015001551A patent/MX364002B/es active IP Right Grant
- 2013-08-05 RU RU2015107303A patent/RU2652989C2/ru active
- 2013-08-05 BR BR112015002357-6A patent/BR112015002357B1/pt active IP Right Grant
- 2013-08-05 CA CA2879798A patent/CA2879798C/fr active Active
- 2013-08-05 WO PCT/US2013/053648 patent/WO2014022858A1/fr active Application Filing
- 2013-08-05 CN CN201380051905.5A patent/CN104981461B/zh active Active
- 2013-08-05 US US14/417,524 patent/US9249116B2/en active Active
-
2015
- 2015-06-11 HK HK15105567.5A patent/HK1205112A1/xx unknown
-
2016
- 2016-02-02 US US15/013,667 patent/US9663482B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2879798C (fr) | 2022-05-31 |
| US20160176833A1 (en) | 2016-06-23 |
| EP2880020A1 (fr) | 2015-06-10 |
| MX2015001551A (es) | 2015-10-08 |
| US9663482B2 (en) | 2017-05-30 |
| JP6265558B2 (ja) | 2018-01-24 |
| KR102157912B1 (ko) | 2020-09-21 |
| BR112015002357A2 (pt) | 2017-07-04 |
| CA2879798A1 (fr) | 2014-02-06 |
| AU2013296187B2 (en) | 2016-09-29 |
| EP2880020B1 (fr) | 2018-11-28 |
| MX364002B (es) | 2019-04-10 |
| BR112015002357B1 (pt) | 2022-03-15 |
| AU2013296187A1 (en) | 2015-02-26 |
| US9249116B2 (en) | 2016-02-02 |
| JP2015524445A (ja) | 2015-08-24 |
| RU2652989C2 (ru) | 2018-05-04 |
| KR20150038390A (ko) | 2015-04-08 |
| RU2015107303A (ru) | 2016-09-27 |
| EP2880020A4 (fr) | 2016-01-20 |
| CN104981461B (zh) | 2017-09-29 |
| CN104981461A (zh) | 2015-10-14 |
| WO2014022858A1 (fr) | 2014-02-06 |
| US20150210659A1 (en) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237309A0 (en) | Benzocyclooctyne compounds and uses thereof | |
| SI2920149T1 (sl) | Spojine 3-aminocikloalkila kot zaviralci receptorja ROR-gama-t in uporaba teh spojin | |
| EP2836212A4 (fr) | Nouvelles compositions et nouveaux procédés | |
| ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| HK1205112A1 (en) | Enzyme-activating compounds and compositions | |
| HK1216250A1 (zh) | '- '-羥基-二氫麥角胺化合物及組合物 | |
| GB201217441D0 (en) | Composition | |
| PL2804487T3 (pl) | Kompozycja | |
| EP2878295A4 (fr) | Composition | |
| GB201218954D0 (en) | Composition | |
| GB201315350D0 (en) | Methods and compositions | |
| GB201315347D0 (en) | Methods and compositions | |
| EP2874641A4 (fr) | Compositions élevant le taux de glutathion et leurs utilisations | |
| GB201206035D0 (en) | Composition | |
| EP2837670A4 (fr) | Composition contenant un fluorobiphényle | |
| EP2910537A4 (fr) | Composition d'agent générant du gaz | |
| EP2910538A4 (fr) | Composition d'agent générant du gaz | |
| GB201209597D0 (en) | Composition | |
| GB201208133D0 (en) | Composition | |
| GB201218195D0 (en) | Composition | |
| LT2830587T (lt) | Odą apsauganti ir odos pusiausvyrą palaikanti kompozicija | |
| GB201214749D0 (en) | Compounds and their uses | |
| GB201222342D0 (en) | Compounds and uses thereof | |
| GB201217915D0 (en) | Composition | |
| GB201215753D0 (en) | Composition |